<DOC>
	<DOCNO>NCT01348126</DOCNO>
	<brief_summary>The purpose study determine whether combine ganetespib ( STA-9090 ) docetaxel effective docetaxel alone treatment subject advance non-small cell lung cancer .</brief_summary>
	<brief_title>Study Ganetespib ( STA-9090 ) + Docetaxel Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Preliminary signal clinical activity ganetespib single agent observe NSCLC . A novel approach treatment NSCLC combination Hsp90 inhibitor , ganetespib , taxanes . Such combination show potential synergy preclinical clinical evaluation Hsp90 inhibitor . Preclinical study ganetespib taxanes indicate combination drug effective either drug alone induce cell death , ongoing phase 1 study indicate combination well tolerated warrant systematic evaluation large study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>confirm diagnosis NSCLC Stage IIIB IV NSCLC ECOG Performance Status 0 1 Prior therapy define 1 prior systemic therapy advance disease measurable disease Radiologic evidence disease progression follow recent prior treatment . Adequate hematologic , hepatic , renal function Active untreated CNS metastasis Active malignancy NSCLC within last 5 year exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin Serious cardiac illness medical condition Pregnant lactate woman Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung cancer</keyword>
</DOC>